Home

The content presented here was prepared by independent authors under the editorial supervision of Creative Educational Concepts, Inc. and does not represent a publication of the American Society of Clinical Oncology. These materials are not sanctioned by ASCO and do not constitute an official part of that meeting.

Target Audience
This activity has been designed to meet the educational needs of oncologists and physicians who are involved in the care and treatment of patients with GU malignancies

Statement of Need
Approximately 339,400 new cases of genitourinary (GU) malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, will be diagnosed in 2007 and approximately 57,120 individuals will die from these diseases in the United States this year. Targeted therapies are an area that hold much promise for the treatment of metastatic RCC and are still being explored in other GU malignancies. The medical community is in the process of defining and understanding the sequence and potential combinations for the treatment of mRCC with newer targeted agents and the results presented at annual meeting of the American Society of Clinical Oncology (ASCO) in 2007 were promising. Results from several ongoing and planned clinical trials will help to answer more questions and provide more hope for patients diagnosed with RCC. It is of utmost importance for oncologists to stay abreast of these newer systemic therapy options through medical education activities that include clinical trial updates from ASCO 2008 in order to improve patient health outcomes.

Educational Objectives
Upon completion of this activity, participants should be better able to:

• Evaluate clinical trial data presented at ASCO based on study design, the reported results, and authors’ conclusions.
• Consider the reviewed data as it relates to previous, current and future treatment of GU malignancies with targeted therapy.
• Consider the rationale for the use of current and emerging therapies in single agent and in combination modalities for renal cell carcinoma.
• Evaluate the current and emerging data for earlier lines of therapy, and various administration methods with respect to overall patient outcomes, safety, and efficacies.

Faculty Information

Nancy A. Dawson, MD Lombardi Comprehensive Cancer Center Georgetown University Washington, DC

Biography
Dr. Nancy A. Dawson is the William M. Scholl Professor of Medicine and Oncology, Director of the Clinical Research Management Office and Director of Clinical Research in the Prostate Cancer Research Center at the Lombardi Comprehensive Cancer Center at Georgetown University. She previously was the Director of Genito-Urinary Medical Oncology at the University of Maryland Greenebaum Cancer Center from 1999 through 2006. Dr. Dawson retired as a colonel in the United States Army in June, 1999. She served her entire military career at Walter Reed Army Medical Center where she was Director of Clinical Research, Chief of Hematology-Oncology Service, and Consultant to the Surgeon General of the Army. She also was a senior investigator in the signal Transduction and Oncogenesis Section of the Medical Branch of the National Cancer Institute. She served as the Vice-Chair of the Prostate Committee for the Cancer and Leukemia Group B (CALGB) for a decade and has chaired several CALGB studies for prostate cancer. She is co-editor of Prostate Cancer (1994) and Prostate Cancer: Translational and Emerging Therapies (2006). She is currently focusing on novel systemic approaches to the treatment of prostate, bladder and kidney cancer. Dr. Dawson earned her undergraduate degree from the University of California, Berkeley, and her medical degree, cum laude, from Georgetown University School of Medicine, Washington, D.C.

Instructions
To receive a statement of credit, you must:

• Review the full content of the activity and reflect upon its teachings
• Complete the questions and evaluation at the end of the activity

Accreditation

Medicine

Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Fee
This activity is complimentary.

Disclosure Declaration
It is the policy of CEC ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems. Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC of any product or manufacturer identified.

Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

Supporting Organization
This activity is supported by an educational grant from Novartis Oncology.

Viewing Requirements
This Website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers.